Across 56 European CTIS lupus Phase II & III trial records, safety and tolerability endpoints were the most frequent endpoint family, appearing in 35 trials, or 62.5%. The disease-specific endpoint pattern split clearly by lupus subtype: SRI-4 dominated systemic lupus erythematosus, renal response dominated lupus nephritis, and CLASI dominated cutaneous lupus.
Safety / tolerability endpoints appeared in 35 of 56 trials, or 62.5%. The next most frequent endpoint families were SLEDAI / PGA / BILAG disease-activity scores in 28 trials, patient-reported outcomes or quality-of-life endpoints in 26 trials, corticosteroid or glucocorticoid reduction in 25 trials, and flare/SFI endpoints in 23 trials.
European lupus endpoint design is not anchored by one universal efficacy measure. Instead, it combines broad safety capture with lupus-specific efficacy scales, patient burden, steroid sparing, and flare prevention.
The 56 trials contained 56 primary endpoint items and 412 secondary endpoint items. Safety/tolerability was the most frequent primary endpoint family at 13 of 56 trials, while secondary endpoints were led by safety/tolerability in 29 trials, disease-activity scores in 28 trials, and PRO/QoL endpoints in 26 trials.
Primary endpoint selection is subtype- and development-stage dependent, while secondary endpoints are where sponsors usually add steroid sparing, PROs, PK/PD, flare, and biomarker support for CTIS/EU submissions.
Three lupus subgroups were large enough for direct comparison: systemic lupus erythematosus (20 trials), lupus nephritis / renal SLE (19 trials), and cutaneous lupus / CLE (12 trials). In systemic SLE, SRI-4 and steroid-reduction endpoints each appeared in 14 of 20 trials; in lupus nephritis, renal function/proteinuria appeared in 15 of 19 trials; and in CLE, CLASI/cutaneous response appeared in 6 of 12 trials.
For CTIS/EU lupus submissions, the clinically credible endpoint anchor depends on the phenotype: SRI-4/BICLA/LLDAS for systemic SLE, CRR/proteinuria/eGFR for lupus nephritis, and CLASI/CLA-IGA for cutaneous lupus.
Phase II accounted for 24 of 56 trials and Phase III for 32 of 56. Safety/tolerability appeared in 19 of 24 Phase II trials, or 79.2%, compared with 16 of 32 Phase III trials, or 50.0%; Phase III primary endpoints were led by SRI-4 in 9 of 32 trials, or 28.1%.
Phase II lupus packages look more exploratory and tolerability-driven, while Phase III packages lean into validated systemic efficacy constructs and confirmatory clinical burden measures.
Three modality groups were large enough for comparison: monoclonal antibody trials appeared in 27 records, small-molecule trials in 22 records, and cell-therapy trials in 12 records. Safety endpoints appeared in 21 of 27 monoclonal-antibody trials, 18 of 22 small-molecule trials, and 8 of 12 cell-therapy trials.
The most distinctive modality signal is cell therapy: DORIS drug-free remission and CRR each appeared in 6 of 12 cell-therapy records, suggesting a stronger remission-reset positioning than conventional lupus drug programs.
Across the 56 included records, the median interval from initial CTIS submission to first authorization was 95 days, with an interquartile range of 35 to 112 days. Phase II and Phase III were nearly identical: 94.5 days for Phase II and 96.0 days for Phase III.
Endpoint complexity did not translate into a clear Phase II versus Phase III timing gap in this cohort. For EU submission planning, lupus nephritis programs showed the shortest median CTIS path among the major lupus subgroups.
The dataset also answers how heavy lupus endpoint packages are and where sponsors place supportive evidence. Across 56 trials, the cohort contained 468 endpoint items, with a median of 4.5 endpoint items per trial; Phase II and Phase III each contributed 234 endpoint items, but Phase II had the higher median endpoint load per trial at 7.5 versus 4.0 for Phase III.
A competitive EU lupus protocol should not rely on one headline endpoint alone. The typical evidence package layers primary efficacy or safety with secondary burden, steroid-sparing, flare, PK/PD, and biomarker support.
SRI-4 means Systemic Lupus Erythematosus Responder Index-4. BICLA means BILAG-based Combined Lupus Assessment. SLEDAI means Systemic Lupus Erythematosus Disease Activity Index. PGA means Physician Global Assessment. LLDAS means Lupus Low Disease Activity State. CLASI means Cutaneous Lupus Erythematosus Disease Area and Severity Index. CRR means complete renal response. SFI means SELENA-SLEDAI Flare Index. PK/PD means pharmacokinetics/pharmacodynamics.